Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Thretide PET/CT in Prostate Cancer
NCT05516329Phase 2Completed
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fibrostatin fluoride [18F] in prostate cancer (PCa), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Detection rate at the patient level, Detection rate at the lesion level and 5 more. Started Aug 2022; status: completed.
02
Drugs
fibrostatin fluoride [18F]
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05516329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516329.